Details

Autor(en) / Beteiligte

• Laguna, Theresa A
• Williams, Cynthia B
• Nunez, Myra G
• Welchlin-Bradford, Cole
• Moen, Catherine E
• Reilly, Cavan S
• Wendt, Chris H

Titel

Biomarkers of inflammation in infants with cystic fibrosis

Ist Teil von

• Respiratory research, 2018-01, Vol.19 (1), p.6-6, Article 6

Ort / Verlag

England: BioMed Central Ltd

Erscheinungsjahr

2018

Quelle

AUTH Library subscriptions: Springer Journals

Beschreibungen/Notizen

• There are urgent needs for clinically relevant biomarkers to identify children with cystic fibrosis (CF) at risk for more progressive lung disease and to serve as outcome measures for clinical trials. Our objective was to investigate three targeted biomarkers in a population of asymptomatic CF infants. Urine, blood and lung function data were collected for 2 years from clinically stable infants diagnosed with CF by newborn screening. A subset of CF infants had bronchoscopy with lavage performed at 6 months and 1 year. Urine was collected quarterly from healthy control infants. Expectorated sputum and urine were collected quarterly for 2 years from clinically stable CF adults. Desmosine, club cell secretory protein (CCSP) and cathepsin B concentrations were measured and compared. Mixed effects models were used to identify associations between biomarker concentrations and clinical characteristics. Receiver operator characteristic curves were generated to investigate the sensitivity and specificity of the biomarkers. Urinary cathepsin B was significantly higher in CF infants compared to healthy infants (p = 0.005). CF infant airway and urinary cathepsin B concentrations were significantly lower compared to adult CF subjects (p = 0.002 & p = 0.022, respectively). CF infant airway CCSP was significantly higher than adult CF subjects (p < 0.001). There was a significant correlation between CF infant plasma CCSP and BALF CCSP (p = 0.046). BALF CCSP was negatively associated with IL-8 (p = 0.017). There was no correlation between biomarker concentration and FEV . Cathepsin B and CCSP show promise as biomarkers of inflammation in CF infants. Further study is needed.